前瞻性血液透析队列中甲状腺功能状态与死亡率
研究纳入南加州17家透析中心的541例血液透析患者,2013至2015年间每6个月重复检测血清TSH。与最低TSH三分位组相比,最高TSH三分位组全因死亡风险独立升高约2.2至2.5倍,排除甲状腺激素补充者后结果相似。
要点
- 血液透析患者中,较高TSH水平与更高的死亡风险独立相关。
- 最高TSH三分位组(2.14至86.7 mIU/L)死亡风险约为最低组(<1.28 mIU/L)的2.2至2.5倍。
- 排除接受甲状腺激素补充治疗的患者后,结果保持一致。
核心结论
- 在时间依赖分析中,高正常至高水平TSH与血液透析患者更高的死亡风险独立相关。
- 原文指出需进一步研究以确定通过甲状腺激素补充使TSH正常化能否改善该人群生存。
研究设计与样本
- 前瞻性队列研究(甲状腺功能、心血管健康与生存研究),纳入南加州17家透析中心的541例血液透析患者。
- 2013至2015年间按方案每6个月重复测量血清TSH水平。
- 采用时间依赖Cox模型估计TSH三分位与死亡率的关联,设四个调整水平;敏感性分析排除接受甲状腺激素补充的患者。
主要发现
- 与最低TSH三分位组(<1.28 mIU/L)相比,最高TSH三分位组(2.14至86.7 mIU/L)在未调整、病例组合、扩展病例组合+实验室、扩展病例组合+实验室+药物模型中的风险比(95%CI)分别为2.54(1.32至4.89)、2.53(1.30至4.93)、2.19(1.11至4.32)、2.28(1.45至3.58)。
- 所有模型中均观察到TSH三分位越高、死亡风险数值越高的趋势。
- 排除接受甲状腺激素补充治疗的患者后,分析结果相似。
关键数值与推荐
- TSH三分位分组:<1.28、1.28至<2.14、2.14至86.7 mIU/L。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT AND OBJECTIVE: Compared with the general population, hemodialysis patients have a substantially higher risk of hypothyroidism, as defined by an elevated serum thyrotropin (TSH) level, and cardiovascular mortality. Whereas an elevated TSH is associated with cardiovascular disease and death in the general population, associations among dialysis patients have been inconsistent. DESIGN, SETTING, PARTICIPANTS, AND MAIN OUTCOME: We examined 541 hemodialysis patients from 17 southern California dialysis centers in the prospective Hypothyroidism, Cardiovascular Health, and Survival study who underwent protocolized measurement of repeated serum TSH levels every 6 months from 2013 to 2015. Associations between TSH tertiles (<1.28, 1.28 to <2.14, and 2.14 to 86.7 mIU/L) and mortality were estimated using time-dependent Cox models with four adjustment levels. In sensitivity analyses, we excluded patients receiving thyroid hormone supplementation. RESULTS: Compared with the lowest TSH tertile, the highest TSH tertile was associated with a 2.2- to 2.5-fold higher mortality risk in unadjusted, case-mix, expanded case-mix+laboratory, and expanded case-mix+laboratory+medication models [hazard ratios (95% confidence interval), 2.54 (1.32 to 4.89), 2.53 (1.30 to 4.93), 2.19 (1.11 to 4.32), and 2.28 (1.45 to 3.58), respectively]. We observed a consistent trend between higher TSH tertiles and numerically higher mortality risk across all models. Similar findings were observed in analyses excluding patients receiving thyroid hormone supplementation. CONCLUSION: In time-dependent analyses, TSH levels in the high-normal to high range were independently associated with higher death risk in hemodialysis patients. Further studies are indicated to determine whether normalization of TSH levels with thyroid hormone supplementation improves survival in this population.
引用
- Rhee CM, You AS, Nguyen DV, et al. Thyroid Status and Mortality in a Prospective Hemodialysis Cohort. J Clin Endocrinol Metab. 2017. PMID: 28324018. doi:10.1210/jc.2016-3616
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。